Lars A. Akslen

43.5k citations

314 papers · 29.1k indexed · 4 hit papers · h-index 67

Impact in

Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.05%
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways

Papers in

Cancer Research 112
- Breast Cancer Treatment Studies 56
- Cancer Genomics and Diagnostics 34
Oncology 143
- Cancer Cells and Metastasis 42
- Cutaneous Melanoma Detection and Management 28

Co-authors: Charles M. Perou Matt van de Rijn Per Eystein Lønning Hilde Johnsen Oddbjørn Straume Helga B. Salvesen Øystein Fluge Thérese Sørlie
Journals: PLoS ONE (17 papers)International Journal of Cancer (16 papers)Apmis (14 papers)Clinical Cancer Research (13 papers)Cancer Research (12 papers)
Partner nations: Norway United States Sweden

In The Last Decade

Lars A. Akslen

304 papers receiving 28.4k citations

Hit Papers

align trajectories log scale

EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast 2005 · 694 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2005 Journal of Clinical Oncology
2004 Clinical Cancer Research
2000 Nature
1996 Nature Medicine

Peers

Countries citing papers authored by Lars A. Akslen

Since Specialization

Citations

This map shows the geographic impact of Lars A. Akslen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars A. Akslen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars A. Akslen more than expected).

Fields of papers citing papers by Lars A. Akslen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars A. Akslen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars A. Akslen. The network helps show where Lars A. Akslen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lars A. Akslen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lars A. Akslen Line = papers co-authored together Lars A. Akslen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tumor necrosis associates with aggressive breast cancer features, increased hypoxia signaling and reduced patient survival Scientific Reports ·A. Achour, D. Barba-González, A. Tegnander, Lars A. Akslen, 伸江村山, Erling A. Høivik	2025	0
2	Distinct clinicopathological features and treatment differences in breast cancer patients of young age Scientific Reports ·Katherine Do, А. С. ЗАВГОРОДНИЙ, Turid Aas, D. T. O., Charolita Oktaviani Sitorus, Lars A. Akslen, 伸江村山, Erling A. Høivik	2025	0
3	Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features Breast Cancer Research ·D. Barba-González, Katherine Do, А. С. ЗАВГОРОДНИЙ, Charolita Oktaviani Sitorus, Ingeborg Winge, Karen Toska, May Britt Kalvenes, Ganesan Nandagopal, مؤنس مصطفى علی, Dokyun Lee, U. Ludwig, Ingunn M. Stefansson, Erling A. Høivik, Lars A. Akslen, Elisabeth Wik	2024	3
4	CD47 and CD68 expression in breast cancer is associated with tumor‐infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis The Journal of Pathology Clinical Research ·Ying Chen, Tor Audun Klingen, Jean-Noël Castorio, Elisabeth Wik, Lars A. Akslen	2023	13
5	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial Clinical Cancer Research ·Carina Strell, M. C. Pound, Erik Holmberg, N. N. Kurshakova, Nabeela AI Kindy, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Wärnberg, Arne Östman	2021	10
6	Interval and Subsequent Round Breast Cancer in a Randomized Controlled Trial Comparing Digital Breast Tomosynthesis and Digital Mammography Screening Radiology ·Solveig Hofvind, Nataliia Moshina, Åsne Sørlien Holen, L.‐M. Laio, Christoph I. Lee, Nehmat Houssami, Hildegunn S. Aase, Lars A. Akslen, Ingfrid S. Haldorsen	2021	26
7	Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma PLoS ONE ·Jussi Pekkanen, Ingeborg Bachmann, Cornelia Schuster, Rita G Ladstein, Lars A. Akslen	2019	21
8	Microvascular proliferation in luminal A and basal-like breast cancer subtypes Journal of Clinical Pathology ·Amalia Timpau, Kristi Krüger, Signe Opdahl, Lars J. Vatten, Lars A. Akslen, Anna M. Bofin	2015	20
9	Spontaneous Reversion of the Angiogenic Phenotype to a Nonangiogenic and Dormant State in Human Tumors Molecular Cancer Research ·Michael S. Rogers, Katherine B. Novak, David Zurakowski, 焦文成, Anna Blois, Eugene Lifshits, Trond Hellem Bø, Anne M. Øyan, Elise R. Bender, Michael Lampa, Soo-Young Kang, Kamila Naxerova, Karl‐Henning Kalland, Oddbjørn Straume, Lars A. Akslen, Randolph S. Watnick, Judah Folkman, George N. Naumov	2014	11
10	Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma Clinical Cancer Research ·Elisabeth Wik, Maria B. Ræder, Camilla Krakstad, Jone Trovik, Even Birkeland, Erling A. Høivik, Siv Mjøs, Henrica M.J. Werner, Monica Mannelqvist, Ingunn M. Stefansson, Anne M. Øyan, Karl H. Kalland, Lars A. Akslen, Helga B. Salvesen	2013	115
11	High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition Clinical Cancer Research ·Elisabeth Wik, Even Birkeland, Jone Trovik, Henrica M.J. Werner, Erling A. Høivik, Siv Mjøs, Camilla Krakstad, Kanthida Kusonmano, 黄滋, Ingunn M. Stefansson, Frederik Holst, Kjell Petersen, Anne M. Øyan, Ronald Simon, Karl H. Kalland, William Ricketts, Lars A. Akslen, Helga B. Salvesen	2013	35
12	Bone Marrow–Derived Gr1+ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1 Cancer Discovery ·Raúl Catena, Nandita Bhattacharya, Tina El Rayes, Suming Wang, Hyejin Choi, Dingcheng Gao, Seongho Ryu, Natasha Joshi, Diane R. Bielenberg, Sharrell B. Lee, Svein A. Haukaas, Karsten Gravdal, Ole J. Halvorsen, Lars A. Akslen, Randolph S. Watnick, Vivek Mittal	2013	102
13	WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence Clinical Cancer Research ·Biaoyang Lin, Angelita G. Utleg, Karsten Gravdal, James T. White, Ole J. Halvorsen, Wei Lu, Lawrence D. True, Robert L. Vessella, Paul H. Lange, Peter S. Nelson, Leroy Hood, Karl-Henning Kalland, Lars A. Akslen	2008	15
14	Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer Molecular Cancer Therapeutics ·Thérese Sørlie, Charles M. Perou, Huihui Fan, Stephanie Geisler, Turid Aas, Andrew B. Nobel, Gun Anker, Lars A. Akslen, David Botstein, Anne‐Lise Børresen‐Dale, Per Eystein Lønning	2006	97
15	Vascular Proliferation Is Important for Clinical Progress of Endometrial Cancer Cancer Research ·Ingunn M. Stefansson, Helga B. Salvesen, Lars A. Akslen	2006	99
16	Significance of tumour‐associated macrophages, vascular endothelial growth factor and thrombospondin‐1 expression for tumour angiogenesis and prognosis in endometrial carcinomas International Journal of Cancer ·Helga B. Salvesen, Lars A. Akslen	1999	6
17	Prognostic impact of morphometric nuclear grade of endometrial carcinoma Cancer ·Helga B. Salvesen, Ole Erik Iversen, Lars A. Akslen	1998	17
18	Prognostic impact of morphometric nuclear grade of endometrial carcinoma Cancer ·Helga B. Salvesen, Ole Erik Iversen, Lars A. Akslen	1998	1
19	Independent prognostic importance of vascular invasion in nodular melanomas Cancer ·Oddbjørn Straume, Lars A. Akslen	1996	3
20	Independent prognostic importance of vascular invasion in nodular melanomas Cancer ·Oddbjørn Straume, Lars A. Akslen	1996	46

About Lars A. Akslen

Lars A. Akslen is a scholar working on Cancer Research, Oncology, Obstetrics and Gynecology, Immunology and Allergy and Reproductive Medicine, having authored 314 papers that have together received 29.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (56 papers), Angiogenesis and VEGF in Cancer (54 papers), Cancer Cells and Metastasis (42 papers), Cancer Genomics and Diagnostics (34 papers), Endometrial and Cervical Cancer Treatments (31 papers), Cutaneous Melanoma Detection and Management (28 papers), Prostate Cancer Treatment and Research (26 papers) and Thyroid Cancer Diagnosis and Treatment (25 papers). The work is most often cited by research in Cancer Research (11.6k citations), Oncology (14.0k citations), Molecular Biology (13.8k citations), Pathology and Forensic Medicine (3.3k citations) and Obstetrics and Gynecology (1.4k citations). Lars A. Akslen has collaborated with scholars based in Norway, United States and Sweden. Frequent co-authors include Charles M. Perou, Matt van de Rijn, Per Eystein Lønning, Hilde Johnsen, Oddbjørn Straume, Helga B. Salvesen, Øystein Fluge, Thérese Sørlie, David Botstein and Christian A. Rees. Their work appears in journals such as PLoS ONE, International Journal of Cancer, Apmis, Clinical Cancer Research and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact